Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome

Ectrodactyly‐ectodermal dysplasia‐clefting (EEC) syndrome is a rare autosomal dominant disease caused by mutations in the p63 gene. To date, approximately 40 different p63 mutations have been identified, all heterozygous. No definitive treatments are available to counteract and resolve the progressi...

Full description

Bibliographic Details
Main Authors: Vanessa Barbaro, Annamaria Assunta Nasti, Paolo Raffa, Angelo Migliorati, Patrizia Nespeca, Stefano Ferrari, Elisa Palumbo, Marina Bertolin, Claudia Breda, Francesco Miceli, Antonella Russo, Luciana Caenazzo, Diego Ponzin, Giorgio Palù, Cristina Parolin, Enzo Di Iorio
Format: Article
Language:English
Published: Wiley 2016-08-01
Series:Stem Cells Translational Medicine
Subjects:
p63
Online Access:https://doi.org/10.5966/sctm.2015-0358
id doaj-dd3ca4149b594fb0b8e26b239e3a0e64
record_format Article
spelling doaj-dd3ca4149b594fb0b8e26b239e3a0e642020-11-25T01:46:43ZengWileyStem Cells Translational Medicine2157-65642157-65802016-08-01581098110510.5966/sctm.2015-0358Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting SyndromeVanessa Barbaro0Annamaria Assunta Nasti1Paolo Raffa2Angelo Migliorati3Patrizia Nespeca4Stefano Ferrari5Elisa Palumbo6Marina Bertolin7Claudia Breda8Francesco Miceli9Antonella Russo10Luciana Caenazzo11Diego Ponzin12Giorgio Palù13Cristina Parolin14Enzo Di Iorio15Fondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Biology, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Neuroscience, University of Naples Federico II, Naples, ItalyDepartment of Biology, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyDepartment of Molecular Medicine, University of Padua, Padua, ItalyFondazione Banca degli Occhi del Veneto, Venice, ItalyEctrodactyly‐ectodermal dysplasia‐clefting (EEC) syndrome is a rare autosomal dominant disease caused by mutations in the p63 gene. To date, approximately 40 different p63 mutations have been identified, all heterozygous. No definitive treatments are available to counteract and resolve the progressive corneal degeneration due to a premature aging of limbal epithelial stem cells. Here, we describe a unique case of a young female patient, aged 18 years, with EEC and corneal dysfunction, who was, surprisingly, homozygous for a novel and de novo R311K missense mutation in the p63 gene. A detailed analysis of the degree of somatic mosaicism in leukocytes from peripheral blood and oral mucosal epithelial stem cells (OMESCs) from biopsies of buccal mucosa showed that approximately 80% were homozygous mutant cells and 20% were heterozygous. Cytogenetic and molecular analyses excluded genomic alterations, thus suggesting a de novo mutation followed by an allelic gene conversion of the wild‐type allele by de novo mutant allele as a possible mechanism to explain the homozygous condition. R311K‐p63 OMESCs were expanded in vitro and heterozygous holoclones selected following clonal analysis. These R311K‐p63 OMESCs were able to generate well‐organized and stratified epithelia in vitro, resembling the features of healthy tissues. This study supports the rationale for the development of cultured autologous oral mucosal epithelial stem cell sheets obtained by selected heterozygous R311K‐p63 stem cells, as an effective and personalized therapy for reconstructing the ocular surface of this unique case of EEC syndrome, thus bypassing gene therapy approaches. Significance This case demonstrates that in a somatic mosaicism context, a novel homozygous mutation in the p63 gene can arise as a consequence of an allelic gene conversion event, subsequent to a de novo mutation. The heterozygous mutant R311K‐p63 stem cells can be isolated by means of clonal analysis and given their good regenerative capacity, they may be used to successfully correct the corneal defects present in this unique case of ectrodactyly‐ectodermal dysplasia‐clefting syndrome.https://doi.org/10.5966/sctm.2015-0358Ectrodactyly-ectodermal dysplasia-clefting syndromeCell therapyp63MosaicismGene conversion
collection DOAJ
language English
format Article
sources DOAJ
author Vanessa Barbaro
Annamaria Assunta Nasti
Paolo Raffa
Angelo Migliorati
Patrizia Nespeca
Stefano Ferrari
Elisa Palumbo
Marina Bertolin
Claudia Breda
Francesco Miceli
Antonella Russo
Luciana Caenazzo
Diego Ponzin
Giorgio Palù
Cristina Parolin
Enzo Di Iorio
spellingShingle Vanessa Barbaro
Annamaria Assunta Nasti
Paolo Raffa
Angelo Migliorati
Patrizia Nespeca
Stefano Ferrari
Elisa Palumbo
Marina Bertolin
Claudia Breda
Francesco Miceli
Antonella Russo
Luciana Caenazzo
Diego Ponzin
Giorgio Palù
Cristina Parolin
Enzo Di Iorio
Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome
Stem Cells Translational Medicine
Ectrodactyly-ectodermal dysplasia-clefting syndrome
Cell therapy
p63
Mosaicism
Gene conversion
author_facet Vanessa Barbaro
Annamaria Assunta Nasti
Paolo Raffa
Angelo Migliorati
Patrizia Nespeca
Stefano Ferrari
Elisa Palumbo
Marina Bertolin
Claudia Breda
Francesco Miceli
Antonella Russo
Luciana Caenazzo
Diego Ponzin
Giorgio Palù
Cristina Parolin
Enzo Di Iorio
author_sort Vanessa Barbaro
title Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome
title_short Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome
title_full Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome
title_fullStr Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome
title_full_unstemmed Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous‐Heterozygous Mosaicism of Ectrodactyly‐Ectodermal Dysplasia‐Clefting Syndrome
title_sort personalized stem cell therapy to correct corneal defects due to a unique homozygous‐heterozygous mosaicism of ectrodactyly‐ectodermal dysplasia‐clefting syndrome
publisher Wiley
series Stem Cells Translational Medicine
issn 2157-6564
2157-6580
publishDate 2016-08-01
description Ectrodactyly‐ectodermal dysplasia‐clefting (EEC) syndrome is a rare autosomal dominant disease caused by mutations in the p63 gene. To date, approximately 40 different p63 mutations have been identified, all heterozygous. No definitive treatments are available to counteract and resolve the progressive corneal degeneration due to a premature aging of limbal epithelial stem cells. Here, we describe a unique case of a young female patient, aged 18 years, with EEC and corneal dysfunction, who was, surprisingly, homozygous for a novel and de novo R311K missense mutation in the p63 gene. A detailed analysis of the degree of somatic mosaicism in leukocytes from peripheral blood and oral mucosal epithelial stem cells (OMESCs) from biopsies of buccal mucosa showed that approximately 80% were homozygous mutant cells and 20% were heterozygous. Cytogenetic and molecular analyses excluded genomic alterations, thus suggesting a de novo mutation followed by an allelic gene conversion of the wild‐type allele by de novo mutant allele as a possible mechanism to explain the homozygous condition. R311K‐p63 OMESCs were expanded in vitro and heterozygous holoclones selected following clonal analysis. These R311K‐p63 OMESCs were able to generate well‐organized and stratified epithelia in vitro, resembling the features of healthy tissues. This study supports the rationale for the development of cultured autologous oral mucosal epithelial stem cell sheets obtained by selected heterozygous R311K‐p63 stem cells, as an effective and personalized therapy for reconstructing the ocular surface of this unique case of EEC syndrome, thus bypassing gene therapy approaches. Significance This case demonstrates that in a somatic mosaicism context, a novel homozygous mutation in the p63 gene can arise as a consequence of an allelic gene conversion event, subsequent to a de novo mutation. The heterozygous mutant R311K‐p63 stem cells can be isolated by means of clonal analysis and given their good regenerative capacity, they may be used to successfully correct the corneal defects present in this unique case of ectrodactyly‐ectodermal dysplasia‐clefting syndrome.
topic Ectrodactyly-ectodermal dysplasia-clefting syndrome
Cell therapy
p63
Mosaicism
Gene conversion
url https://doi.org/10.5966/sctm.2015-0358
work_keys_str_mv AT vanessabarbaro personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT annamariaassuntanasti personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT paoloraffa personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT angelomigliorati personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT patrizianespeca personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT stefanoferrari personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT elisapalumbo personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT marinabertolin personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT claudiabreda personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT francescomiceli personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT antonellarusso personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT lucianacaenazzo personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT diegoponzin personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT giorgiopalu personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT cristinaparolin personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
AT enzodiiorio personalizedstemcelltherapytocorrectcornealdefectsduetoauniquehomozygousheterozygousmosaicismofectrodactylyectodermaldysplasiacleftingsyndrome
_version_ 1725017596182396928